Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes

NCT02008318 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02008318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02008318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2014
Completion date
September 30, 2017
Enrollment
43 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes